Llwytho...
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Jpn J Clin Oncol |
|---|---|
| Prif Awduron: | , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Oxford University Press
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4412139/ https://ncbi.nlm.nih.gov/pubmed/25647781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv011 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|